1842 related articles for article (PubMed ID: 33725836)
1. Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report.
Xu J; Xu X; Chen J; Wang J; Jiang C; Lv C; Chen B
Medicine (Baltimore); 2021 Mar; 100(10):e24824. PubMed ID: 33725836
[TBL] [Abstract][Full Text] [Related]
2. Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study.
Gao Y; He H; Li X; Zhang L; Xu W; Feng R; Li W; Xiao Y; Liu X; Chen Y; Wang X; Bai B; Wu H; Cai Q; Li Z; Li J; Lin S; He Y; Ping L; Huang C; Mao J; Chen X; Zhao B; Huang H
Signal Transduct Target Ther; 2024 May; 9(1):121. PubMed ID: 38755119
[TBL] [Abstract][Full Text] [Related]
3. Sintilimab combined with chidamide in the treatment of extranodal nature killer/T-cell lymphoma with secondary hemophagocytic lymphohistiocytosis: Two case reports and literature review.
Xu QY; Yang HY; Li MW; He ZD; Hong HY; Peng ZG
Medicine (Baltimore); 2022 Sep; 101(38):e30731. PubMed ID: 36197207
[TBL] [Abstract][Full Text] [Related]
4. First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial.
Tian XP; Cai J; Xia Y; Zhang YC; Wang L; Liu PP; Huang HQ; Li YJ; Zhou H; Li ZM; Yang J; Wei LQ; Zou QH; Huang Y; Li J; Ling L; Zhong WL; Cai QQ
Lancet Haematol; 2024 May; 11(5):e336-e344. PubMed ID: 38554717
[TBL] [Abstract][Full Text] [Related]
5. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
[TBL] [Abstract][Full Text] [Related]
6. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
[TBL] [Abstract][Full Text] [Related]
7. Comparative Study of L-Asparaginase-Based LOP Regimen Over CHOP Regimen Before Radiotherapy for Stage IIE Extranodal Nasal Type NK/T Cell Lymphoma: A Study of 2 Centers.
Huang L; Yuan B; Wu H; Chu H; Liu Y; Wu S; Li H; Lu H; Chen H
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):152-158. PubMed ID: 28215935
[TBL] [Abstract][Full Text] [Related]
8. Chidamide induces long-term remission in rare subcutaneous panniculitis-like T-cell lymphoma: An unusual case report and literature review.
Li L; Wu C; Chai Y; Dong C; Zhao L
Int J Immunopathol Pharmacol; 2021; 35():20587384211009342. PubMed ID: 33845613
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
Wei W; Wu P; Li L; Zhang ZH
Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702
[TBL] [Abstract][Full Text] [Related]
10. "Sandwich" protocol based on modified SMILE regimen for children with newly extranodal NK/T cell lymphoma, nasal type: a single-arm, single-center clinical study.
Shen CQ; He GQ; Wan Z; Lin C; Yang X; Lu XX; Zhu YP; Gao J; Guo X
Ann Hematol; 2023 Nov; 102(11):3143-3152. PubMed ID: 37486391
[TBL] [Abstract][Full Text] [Related]
11. Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study.
Wang H; Wuxiao ZJ; Zhu J; Wang Z; Wang KF; Li S; Chen X; Lu Y; Xia ZJ
Leuk Lymphoma; 2015 Apr; 56(4):971-7. PubMed ID: 24991715
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
Miyazaki K; Suzuki R; Oguchi M; Taguchi S; Amaki J; Maeda T; Kubota N; Maruyama D; Terui Y; Sekiguchi N; Takizawa J; Tsukamoto H; Murayama T; Ando T; Matsuoka H; Hasegawa M; Wada H; Sakai R; Kameoka Y; Tsukamoto N; Choi I; Masaki Y; Shimada K; Fukuhara N; Utsumi T; Uoshima N; Kagami Y; Asano N; Ejima Y; Katayama N; Yamaguchi M
Hematol Oncol; 2022 Oct; 40(4):667-677. PubMed ID: 35142384
[TBL] [Abstract][Full Text] [Related]
13. Intensive therapy can improve long-term survival in newly diagnosed, advanced-stage extranodal NK/T-cell lymphoma: A multi-institutional, real-world study.
Wei YC; Qi F; Zheng BM; Zhang CG; Xie Y; Chen B; Liu WX; Liu WP; Fang H; Qi SN; Zhang D; Chai Y; Li YX; Wang WH; Song YQ; Zhu J; Dong M
Int J Cancer; 2023 Nov; 153(9):1643-1657. PubMed ID: 37539660
[TBL] [Abstract][Full Text] [Related]
14. Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases.
Du L; Zhang L; Li L; Li X; Yan J; Wang X; Fu X; Sun Z; Zhang X; Li Z; Wu J; Yu H; Chang Y; Zhou Z; Nan F; Wu X; Tian L; Zhang M
Onco Targets Ther; 2020; 13():7189-7197. PubMed ID: 32801749
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
Wang JH; Wang L; Liu CC; Xia ZJ; Huang HQ; Lin TY; Jiang WQ; Lu Y
Oncotarget; 2016 May; 7(20):29092-101. PubMed ID: 27093153
[TBL] [Abstract][Full Text] [Related]
16. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
[TBL] [Abstract][Full Text] [Related]
17. Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report.
Wang J; Gao YS; Xu K; Li XD
World J Clin Cases; 2022 Feb; 10(5):1609-1616. PubMed ID: 35211600
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study.
Tian J; Hao M; Liu Q; Xiao F; Li Y; Qi M; Gao J; Liu L; Yin D
Hematol Oncol; 2023 Aug; 41(3):396-406. PubMed ID: 36516297
[TBL] [Abstract][Full Text] [Related]
19. Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy.
Wang Z; Xu H; Mei Y; Xiao M; Cao Y; Huang L; Yang Z; Zhang Y; Han Z; Zheng M; Hong Z
Int Immunopharmacol; 2024 May; 133():112014. PubMed ID: 38615378
[TBL] [Abstract][Full Text] [Related]
20. First-line LVDP (L-asparaginase, etoposide, dexamethasone, and cisplatin) regimen combined with radiotherapy is effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type.
Wu W; Chen X; Li N; Luo Q; Zou L
Ann Hematol; 2022 Jul; 101(7):1557-1565. PubMed ID: 35585247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]